BofA raised the firm’s price target on McKesson (MCK) to $900 from $850 and keeps a Buy rating on the shares. The firm is increasing its target multiples for McKesson and Cencora (COR) following peer Cardinal Health’s (CAH) strong quarter highlighting the robust demand environment and positive broad-based industry utilization trends, the analyst tells investors. McKesson will report fiscal Q2 earnings after market close on November 5, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- MCK Earnings this Week: How Will it Perform?
- McKesson price target raised to $920 from $860 at UBS
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Citius Oncology announces distribution agreement with McKesson